乳腺癌内乳淋巴结转移的优化放疗方案
本研究回顾性分析84例临床内乳淋巴结转移(cIMN+)乳腺癌患者,均接受根治性手术、紫杉类化疗及术后放疗。中位随访58个月,5年局部区域无复发生存率89.1%、无病生存率(DFS)72.0%、总生存率81.2%。三阴性亚型、IMN大小≥1.0 cm、高龄及低剂量IMN放疗与较差DFS显著相关;IMN≥1.0 cm患者中高剂量IMN放疗5年DFS显著优于低剂量(69.3% vs 33.3%,p=0.019)。
要点
- cIMN+乳腺癌术后IMN放疗不手术可获较好局部控制。
- IMN≥1.0 cm者高剂量IMN放疗DFS优于低剂量。
- 三阴性、高龄、IMN≥1.0 cm及低剂量与差DFS相关。
核心结论
- cIMN+乳腺癌患者接受IMN放疗而未行IMN清扫可获得良好结局。
- 对于IMN较大的患者,可能需要更高的IMN放疗剂量以控制疾病。
研究设计与样本
- 回顾性研究纳入84例cIMN+乳腺癌患者,均接受根治性手术、紫杉类化疗和术后放疗。
- 术后全乳或胸壁放疗剂量为50 Gy/2 Gy分次,IMN推量由医生决定。
- 按IMN剂量分为低剂量组(50.0-63.5 Gy)和高剂量组(63.6-70.4 Gy)。
主要发现
- 中位随访58个月(范围12-111个月),IMN复发2例(2.4%),均同时伴远处转移。
- 5年局部区域无复发生存率、DFS和总生存率分别为89.1%、72.0%和81.2%。
- 三阴性亚型、IMN大小≥1.0 cm、高龄和低剂量IMN与较差DFS显著相关。
- IMN≥1.0 cm患者中,高剂量IMN组5年DFS显著高于低剂量组(69.3% vs 33.3%,p=0.019)。
关键数值与推荐
- IMN剂量分组:低剂量50.0-63.5 Gy,高剂量63.6-70.4 Gy。
- 全乳或胸壁放疗剂量50 Gy,分次2 Gy。
- IMN≥1.0 cm患者高剂量IMN放疗5年DFS 69.3%,低剂量33.3%,p=0.019。
临床怎么用
- cIMN+乳腺癌术后可考虑IMN放疗而不行IMN清扫。
- 对IMN大小≥1.0 cm的患者,可考虑给予更高IMN放疗剂量以改善DFS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to determine the optimal radiotherapy (RT) regimen for patients with clinical metastasis to the internal mammary lymph node (cIMN+) from breast cancer. METHODS: We retrospectively reviewed the medical records of 84 patients with cIMN+ breast cancer treated with curative surgery, taxane-based chemotherapy, and postoperative RT between January 2009 and December 2014. Postoperative RT was administered to the whole breast or chest wall using 50 Gy in 2 Gy fractions. Boost RT to the internal mammary lymph node (IMN) was administered at the physician's discretion. We categorized patients into two groups according to the IMN dose as follows: low-dose IMN RT (50.0-63.5 Gy) and high-dose IMN RT (63.6-70.4 Gy). RESULTS: After a median follow-up of 58 months (range, 12-111 months), IMN recurrence was observed in 2 patients (2.4%), and all IMN recurrences developed simultaneously with distant metastases. The 5-year locoregional recurrence-free survival, disease-free survival (DFS), and overall survival rates were 89.1, 72.0, and 81.2%, respectively. The triple-negative subtype, IMN size ≥1.0 cm, old age, and low-dose IMN were significantly associated with poor DFS. Among the patients with IMN size ≥1.0 cm, the 5-year DFS was significantly higher in those treated with high-dose IMN RT than in those treated with low-dose IMN RT (69.3% vs. 33.3%, p = 0.019). CONCLUSIONS: IMN RT without IMN dissection resulted in favorable outcomes in cIMN+ breast cancer. For patients with a large IMN, a higher IMN radiation dose might be needed for disease control.
引用
- Yang K, Kim H, Choi DH, et al. Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer. Radiat Oncol. 2020. PMID: 32122399. doi:10.1186/s13014-020-1464-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。